Pirfenidone Reverts Global DNA Hypomethylation, Promoting DNMT1/UHRF/PCNA Coupling Complex in Experimental Hepatocarcinoma
Authors:
- Hipolito Otoniel Miranda-RobleroHMHipolito Otoniel Miranda-Roblero
- Liliana Faridi Saavedra-SalazarLSLiliana Faridi Saavedra-Salazar
- Marina Galicia-MorenoMGMarina Galicia-Moreno
- Scarlet Arceo-OrozcoSAScarlet Arceo-Orozco
- Fernando Caloca-CamarenaFCFernando Caloca-Camarena
- Ana Sandoval-RodriguezASAna Sandoval-Rodriguez
- Jesús García-BañuelosJesús García-Bañuelos
- Claudia Frias-GonzalezCFClaudia Frias-Gonzalez
- Mónica Almeida-LópezMAMónica Almeida-López
- Erika Martínez-LópezEMErika Martínez-López
- Juan Armendariz-BorundaJAJuan Armendariz-Borunda
- Hugo Christian Monroy-RamirezHMHugo Christian Monroy-Ramirez
Open Access
Abstract
Hepatocellular carcinoma (HCC) development is associated with altered modifications in DNA methylation, changing transcriptional regulation. Emerging evidence indicates that DNA methyltransferase 1 (DNMT1) plays a key role in the carcinogenesis process. This study aimed to investigate how pirfenidone (PFD) modifies this pathway and the effect generated by the association between c-Myc expression and DNMT1 activation. Rats F344 were used for HCC development using 50 mg/kg of diethylnitrosamine (DEN) and 25 mg/kg of 2-Acetylaminofluorene (2-AAF). The HCC/PFD group received simultaneous doses of 300 mg/kg of PFD. All treatments lasted 12 weeks. On the other hand, HepG2 cells were used to evaluate the effects of PFD in restoring DNA methylation in the presence of the inhibitor 5-Aza. Histopathological, biochemical, immunohistochemical, and western blot analysis were carried out and our findings showed that PFD treatment reduced the amount and size of tumors along with decreased Glipican-3, β-catenin, and c-Myc expression in nuclear fractions. Also, this treatment improved lipid metabolism by modulating PPARγ and SREBP1 signaling. Interestingly, PFD augmented DNMT1 and DNMT3a protein expression, which restores global methylation, both in our in vivo and in vitro models. In conclusion, our results suggest that PFD could slow down HCC development by controlling DNA methylation.Keywords
All Related Versions
Funding Information
- Fondo Universidad de Guadalajara, Programa de Fortalecimiento de Institutos, Centros y Laboratorios de Investigación (2022-0034, PIN 2020-I-2963099, 320341)
- Fondo para Proyectos de Impulso a la Investigación (2022-0034, PIN 2020-I-2963099, 320341)
- Fondo CONAHCyT Ciencia Básica y/o Ciencia de Frontera, Modalidad: Paradigmas y Controversias de la Ciencia 2022 (2022-0034, PIN 2020-I-2963099, 320341)
This publication has 45 references indexed in Scilit:
- DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlationInternational Journal of Molecular Medicine, 2007
- The Epigenomics of CancerCell, 2007
- Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt SignalingCancer Research, 2005
- Peroxisome Proliferator-Activated Receptor γ Inhibition Prevents Adhesion to the Extracellular Matrix and Induces Anoikis in Hepatocellular Carcinoma CellsCancer Research, 2005
- The epigenetics of cancer etiologySeminars in Cancer Biology, 2004
- Chromosomal Instability and Tumors Promoted by DNA HypomethylationScience, 2003
- Molecular pathogenesis of human hepatocellular carcinomaNature Genetics, 2002
- Involvement of P21Waf1/Cip1, P27Kip1, and P18Ink4c in Troglitazone–Induced Cell–Cycle Arrest in Human Hepatoma Cell LinesHepatology, 2001
- Analyses of proliferating cell nuclear antigen‐positive cells in hepatocellular carcinoma: Comparisons with clinical findingsJournal of Gastroenterology and Hepatology, 1994
- Comparative effects of L-methionine, S-adenosyl-L-methionine and 5'-methylthioadenosine on the growth of preneoplastic lesions and DNA methylation in rat liver during the early stages of hepatocarcinogenesis.1991